慢性丁型肝炎病毒 (HDV) 感染是最严重的病毒性肝炎形式，具有很高的终末期肝病和肝细胞癌发生率。因此，迫切需要有效的抗病毒治疗策略。直到最近，抗病毒治疗仅限于聚乙二醇化干扰素-α。随着欧洲药品管理局对进入抑制剂布列韦肽的有条件批准，现在可以使用新的治疗方案。此外，目前在临床 II 和 III 期试验中测试了多种其他抗病毒化合物，它们代表了治疗慢性 HDV 感染的有希望的药物。
New Treatments for Chronic Hepatitis B Virus/Hepatitis D Virus Infection
Lisa Sandmann 1 , Heiner Wedemeyer 2
Affiliations
Affiliations
1
Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str. 1, Hannover 30625, Germany.
2
Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str. 1, Hannover 30625, Germany; German Center for Infection Research (DZIF), Partner Side Hannover/Braunschweig. Electronic address: [email protected].
PMID: 34593156 DOI: 10.1016/j.cld.2021.06.011
Abstract
Chronic hepatitis D virus (HDV) infection is the most severe form of viral hepatitis with high rates of end-stage liver disease and hepatocellular carcinoma. Therefore, effective antiviral treatment strategies are needed desperately. Until recently, antiviral treatment was limited to pegylated interferon-alpha. With the conditional approval of the entry inhibitor bulevirtide by the European Medicines Agency, new treatment options are now available. In addition, multiple other antiviral compounds are currently tested in clinical phase II and III trials and represent promising agents for the treatment of chronic HDV infection.